All In Biotech

Drug Trial Radar · NCT03936361

Statins In Intracerbral Hemorrhage

STATINS USE IN INTRACEREBRAL HEMORRHAGE PATIENTS

Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,456 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,456

Planned (sponsor's estimate)

Start

Jun 10, 2020

Primary completion

Dec 31, 2028

Study completion Dec 2029

Sponsor

Lead sponsor
Beth Israel Deaconess Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
NINDS Stroke Trials Network (StrokeNet); Canadian Stroke Consortium (CSC); University of Cincinnati; Medical University of South Carolina; Yale University; MetroHealth Medical Center; UH, Cleveland Medical Center; Corewell Health West; West Virginia University; Columbia University; Weill Medical College of Cornell University; New York Presbyterian Brooklyn Methodist Hospital; Buffalo General Medical Center; State University of New York - Upstate Medical University; St. Joseph's Regional Medical Center, New Jersey; Tufts Medical Center; Massachusetts General Hospital; UMass Memorial Health; Brigham and Women's Hospital; Baystate Medical Center; University of Vermont Medical Center; Lahey Hospital & Medical Center; Augusta University Medical Center; Prisma Health-Upstate; The Moses H. Cone Memorial Hospital; University of Virginia; George Washington University; University of Maryland, Baltimore; Mount Sinai Hospital, New York; NYU Langone Medical Center - Tisch Hospital; Montefiore Medical Center; NYU Langone Hospital - Brooklyn; Froedtert Hospital; Central DuPage Hospital; Rush University Medical Center; Loyola University; Stanford University; Mercy San Juan Medical Center; Oregon Health and Science University; Kaiser Permanente; University of Southern California; Cedars-Sinai Medical Center; University of New Mexico; Long Beach Memorial Medical Center; University of California, Irvine; Arrowhead Regional Medical Center; Huntington Memorial Hospital; Scripps Health; University of California, San Diego; Ochsner Health System; St. Joseph's Hospital and Medical Center, Phoenix; Desert Care Network; Eden Medical Center; San Francisco General Hospital; University of California, San Francisco; University of Louisville; Ohio State University; University of Iowa; Sanford Medical Center Fargo; University of Nebraska; Tampa General Hospital; University of Florida; Jackson Health System; Mayo Clinic; Baptist Medical Center Jacksonville; Wayne State University; University of Michigan; Mercy Health Saint Mary Grand Rapids; Metro Health, Michigan; University of Kentucky; McLaren Health Care; Regions Hospital; Allina Health System; University of Kansas; University of Minnesota; St. Cloud Hospital; Milton S. Hershey Medical Center; Abington Memorial Hospital; Temple University; University of Pennsylvania; Lehigh Valley Hospital; York Hospital, York, PA; Thomas Jefferson University; University of Pittsburgh; St. David's HealthCare; Baylor College of Medicine; Tulane Medical Center; The University of Texas Health Science Center at San Antonio; OU Medical Center; University of Utah; Swedish Medical Center; St. Mary's Medical Center; Banner University Medical Center; Intermountain Health Care, Inc.; Legacy Emanuel Medical Center; Sacred Heart Medical Center Springfield; Harborview Injury Prevention and Research Center; University of Wisconsin, Madison; Aurora BayCare Medical Center; Wake Forest University Health Sciences; University of Alabama at Birmingham; University of South Alabama; Carolinas Medical Center; Barnes-Jewish Hospital; St. Luke's Hospital, Kansas City, Missouri; University of Arkansas; OSF Healthcare System; Cox Medical Center South; North Shore University Hospital; Rhode Island Hospital; Hartford Hospital; Staten Island University Hospital; Johns Hopkins University; University of North Carolina, Chapel Hill; University of Alberta; The Ottawa Hospital; London Health Sciences Centre; Hamilton General Hospital; Hopital de l'Enfant-Jesus; Montreal Neurological Institute and Hospital; Foothills Medical Centre; University Health Network, Toronto; Health Sciences Centre, Winnipeg, Manitoba; Thunder Bay Regional Health Sciences Centre; Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre; Fraser Health; Hopital de Chicoutimi; Université de Sherbrooke
First posted
May 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The SATURN trial aims to determine whether continuation vs. discontinuation of statin drugs after spontaneous lobar intracerebral hemorrhage (ICH) is the best strategy; and whether the decision to continue/discontinue statins should be influenced by an individual's Apolipoprotein-E (APOE) genotype. An MRI ancillary study (SATURN MRI), in a subset of SATURN participants , will evaluate the effects of continuation vs. discontinuation of statin drugs on hemorrhagic and ischemic MRI markers of cerebral small vessel disease, and whether the presence/burden of hemorrhagic markers (i.e. cerebral microbleeds and/or cortical superficial siderosis) on baseline MRI influences the risk of ICH recurrence on/off statin therapy.

Conditions

  • Intracerebral Hemorrhage

Interventions

  • StatinsDrug

    Statin drugs (already prescribed) at ICH onset will be either continued or discontinued by the participants following qualifying ICH

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrent symptomatic ICHTime frame: within 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.